Last updated: August 4, 2026
Fomepizole is a small, hospital-administered antidote used for methanol and ethylene glycol poisoning. Its market is structurally small but strategically important because treatment is time-sensitive, therapeutic substitution is limited, and hospitals maintain emergency inventories. The active ingredient has no meaningful new-molecule exclusivity remaining. Commercial performance depends on poisoning incidence, emergency preparedness, product availability, generic competition, contract supply, and episodic shortage conditions rather than broad prescription growth.
No manufacturer publicly reports standalone fomepizole revenue. The product is generally embedded in broader hospital, critical-care, or specialty-pharmaceutical revenue categories. A reliable global market-size or product-level revenue figure cannot be established from public company filings.
What is fomepizole and how is it used?
Fomepizole is an alcohol dehydrogenase inhibitor. It blocks the conversion of methanol and ethylene glycol into toxic metabolites. The FDA-approved product is administered intravenously and is used with hemodialysis when clinically indicated.
| Attribute |
Fomepizole |
| Active ingredient |
Fomepizole |
| Original branded product |
Antizol |
| FDA indication |
Methanol or ethylene glycol poisoning |
| Administration |
Intravenous injection |
| Primary setting |
Emergency department, intensive care unit, toxicology service |
| Treatment role |
Antidote, often combined with hemodialysis |
| Main alternatives |
Ethanol, hemodialysis, supportive and critical-care treatment |
| Prescribing model |
Acute, episodic, hospital-based |
| Chronic outpatient market |
None |
The commercial product is typically supplied as a concentrated solution in single-dose vials. Treatment requires an initial loading dose followed by repeated maintenance doses. The dosing schedule and product consumption increase when dialysis is used because fomepizole dosing is adjusted around the dialysis session.[1]
How large is the fomepizole market?
The fomepizole market is a niche emergency-medicine market with low annual patient volume relative to mainstream pharmaceutical categories. Demand is concentrated in hospitals that treat toxic alcohol exposures or maintain antidote inventories under emergency preparedness protocols.
Public surveillance does not provide a clean conversion from poisoning events to fomepizole units or revenue. Reported cases include suspected exposures, referrals, poison-center consultations, and patients who may receive ethanol, dialysis, or supportive care rather than fomepizole.
What drives fomepizole demand?
Key demand drivers include:
- Methanol and ethylene glycol exposures.
- Antifreeze ingestion or accidental exposure.
- Industrial and laboratory solvent exposure.
- Intentional ingestion.
- Contaminated or illicit alcohol events.
- Hospital stocking requirements.
- Poison-center treatment protocols.
- Increased recognition of toxic alcohol poisoning.
- Regional emergency preparedness policies.
The market is relatively insensitive to conventional pharmaceutical promotion. Physicians generally use fomepizole when toxic alcohol poisoning is suspected because delaying treatment can increase the risk of severe metabolic acidosis, visual injury, renal failure, neurologic damage, or death.
Why does the market remain commercially defensible?
Fomepizole has several demand characteristics that support pricing and recurring orders:
- Hospitals need immediate access rather than just-in-time delivery.
- The product is used in high-acuity cases where clinical urgency reduces price sensitivity.
- Product substitution is limited when ethanol is difficult to dose or monitor.
- Inventory turns are unpredictable, but hospitals cannot eliminate stock without accepting clinical risk.
- Each treated patient may require several vials, especially when dialysis is performed.
The same characteristics make annual demand volatile. A hospital may hold inventory for long periods, then place a large replenishment order after one poisoning case.
What is the FDA regulatory status of fomepizole?
Fomepizole was approved by the FDA as Antizol in 1997. The FDA-approved use is treatment of ethylene glycol and methanol poisoning.[1]
The regulatory pathway is now mature:
| Regulatory element |
Status |
| New drug approval |
Established |
| New-chemical-entity exclusivity |
Expired |
| Pediatric exclusivity |
No current commercial relevance identified |
| Orphan-drug exclusivity |
Not the principal current market barrier |
| Generic pathway |
Available through abbreviated approval mechanisms |
| Current market structure |
Branded and generic injectable supply |
| Biosimilar exposure |
None |
Fomepizole is a chemically synthesized small molecule, not a biologic. Biosimilar competition is therefore irrelevant. Competition occurs through generic injectable products, branded supply, hospital purchasing contracts, and inventory availability.
What patents protect fomepizole?
The original composition-of-matter protection for fomepizole is no longer commercially relevant. Fomepizole was known and used before its 1997 FDA approval, and the original Antizol approval dates to the late 1990s.
How strong is the current fomepizole patent estate?
The current patent estate is weak as a barrier to generic entry because:
- The active ingredient is an old small molecule.
- The original branded product has been marketed for decades.
- The principal dosage form is a conventional intravenous solution.
- No complex delivery technology is required.
- The commercial value lies in emergency availability and regulatory supply, not in molecule-level exclusivity.
Any later formulation, manufacturing, or packaging patents would have narrower scope than a composition patent and would not necessarily prevent approval of a conventional generic fomepizole injection. A generic manufacturer could potentially design around a narrow process or container claim while retaining the same active ingredient and therapeutic use.
What is the Orange Book status of fomepizole?
The Orange Book is relevant to FDA-approved branded and generic drug products, but the practical exclusivity question is whether an unexpired, enforceable patent blocks approval or launch. Fomepizole’s principal commercial protection is not based on an active new-molecule patent.
The FDA-listed reference product is Antizol. Generic approval status and any product-specific patent entries should be checked against the current FDA Orange Book record because listings, manufacturers, and marketing status can change.[2] The absence of meaningful active patent protection does not eliminate commercial barriers created by manufacturing validation, sterile-filling capacity, supply interruptions, or hospital contracting.
When does fomepizole lose exclusivity?
Fomepizole has already lost the exclusivity associated with its original approval. Antizol’s commercial position is therefore post-exclusivity.
The relevant timeline is:
| Period |
Event |
Commercial effect |
| Before 1997 |
Fomepizole known as an alcohol dehydrogenase inhibitor |
Limited patent-based differentiation |
| 1997 |
FDA approval of Antizol |
Establishes branded reference product |
| 2000s |
Expansion of toxicology use and hospital stocking |
Builds institutional demand |
| 2010s onward |
Generic injectable competition develops |
Reduces reliance on the originator |
| Current market |
Mature, low-volume emergency antidote |
Supply and contracts determine share |
There is no standard future “loss of exclusivity” event comparable to a blockbuster biologic or patented chronic medicine. The principal loss-of-exclusivity event has already occurred.
Which companies are challenging the fomepizole franchise?
Generic manufacturers, rather than branded innovators, represent the principal competitive threat. Public market information identifies fomepizole injection products from multiple suppliers over time, including branded and generic hospital-pharmacy manufacturers. Supplier participation can change because sterile injectables are vulnerable to manufacturing interruptions and commercial discontinuation.
The competitive set may include:
- Antizol and its commercial successor or distributor.
- Generic injectable manufacturers.
- Hospital and specialty-pharmacy suppliers.
- Compounded or alternative ethanol protocols in selected institutions.
A definitive current manufacturer-by-manufacturer market-share ranking is not available from public filings. Companies generally do not report fomepizole units, net pricing, or revenue separately.
Are there Paragraph IV challenges to fomepizole patents?
Paragraph IV litigation is not a central current risk for fomepizole. The product is old, and its commercial position is not dependent on a high-value, late-expiring patent estate.
A generic applicant could still use an ANDA certification strategy if a relevant patent appeared in the Orange Book. That legal mechanism does not create a durable barrier where the relevant patents are expired, absent, narrow, or nonblocking. Publicly visible litigation risk is therefore more likely to arise from:
- Product liability claims.
- Manufacturing or quality disputes.
- Contracting disagreements.
- Distribution rights.
- Patent disputes involving a specific formulation or manufacturing process.
No major, publicly established Paragraph IV litigation campaign defines the current fomepizole market.
What formulation patents protect fomepizole injection?
The standard product is a conventional injectable solution. That limits the opportunity for durable formulation exclusivity.
Potentially protectable attributes could include:
- Concentration and solvent system.
- Container closure configuration.
- Stability profile.
- Manufacturing process.
- Packaging designed for emergency use.
- Shelf-life or storage conditions.
These features can support regulatory or operational differentiation, but they generally provide weaker protection than a composition-of-matter patent. A formulation patent would also need to cover a feature that is difficult for generic manufacturers to avoid while preserving an acceptable injectable product.
The more important technical barrier is sterile manufacturing. Fomepizole is not difficult to synthesize, but injectable production requires qualified facilities, validated aseptic processes, quality systems, stability data, and reliable regulatory compliance.
What patent litigation affects fomepizole?
No major patent litigation is widely associated with the core fomepizole market. The molecule’s age and the presence of generic injectable products reduce the incentive for extensive patent litigation.
Commercial disputes are more likely to focus on:
- Distribution agreements.
- Product shortages.
- Hospital purchasing arrangements.
- Manufacturing transfers.
- Regulatory compliance.
- Recall or quality events.
For investors and business-development teams, litigation surveillance should focus on current Orange Book entries, FDA approvals, drug-shortage notices, manufacturer discontinuations, and contract changes rather than assuming a conventional patent-cliff dispute.
How does fomepizole compare with ethanol as an antidote?
Fomepizole is usually preferred because dosing is more predictable and it does not create ethanol intoxication. Ethanol remains a potential alternative where fomepizole is unavailable or cost constraints are significant.
| Factor |
Fomepizole |
Ethanol |
| Mechanism |
Alcohol dehydrogenase inhibition |
Competitive alcohol dehydrogenase substrate |
| Dosing |
Structured and relatively predictable |
Requires close concentration monitoring |
| Toxicity management |
Generally easier |
Hypoglycemia, intoxication, and monitoring concerns |
| Hospital use |
Preferred in many protocols |
Alternative or contingency therapy |
| Supply risk |
Injectable manufacturing and inventory risk |
Pharmaceutical-grade availability and monitoring requirements |
| Commercial position |
Premium antidote |
Lower-cost substitute in selected settings |
Fomepizole’s value is strongest when clinical staff prioritize predictable dosing and rapid protocol execution. Ethanol constrains the maximum price that fomepizole suppliers can charge, but it does not fully eliminate demand because the two products have different operational profiles.[3]
What generic entry risks exist for fomepizole?
Generic entry risk is high from a patent perspective but moderated by the economics of sterile injectable manufacturing.
Generic risks
- Minimal active-ingredient exclusivity.
- Conventional dosage form.
- Established FDA approval pathway.
- Limited need for clinical differentiation.
- Potential price competition among hospital suppliers.
Barriers to generic success
- Small market size.
- Unpredictable purchasing volume.
- Need to maintain emergency inventory.
- Sterile injectable manufacturing costs.
- Shortage and quality-control risk.
- Hospital formulary and contract requirements.
- Low incentive to enter without dependable distribution.
This produces a market that can support several approved suppliers but may still experience shortages if one manufacturer exits or faces a production problem. The number of approved suppliers is therefore not equivalent to the number of dependable commercial suppliers.
What is the financial trajectory for fomepizole?
Fomepizole revenue is likely to remain stable to modestly growing in nominal terms, but public information does not support a precise revenue forecast. The product does not have the patient population or refill frequency required for blockbuster expansion.
Revenue drivers
- Treatment price per vial.
- Number of hospitals stocking the product.
- Average vials used per case.
- Dialysis frequency.
- Generic and branded mix.
- Contract discounts.
- Shortage-related price changes.
- Toxic alcohol exposure trends.
- Hospital inventory policies.
Financial constraints
- Low patient volume.
- Limited repeat use by individual patients.
- Generic pricing pressure.
- Hospital purchasing leverage.
- Product wastage from expiration.
- Potential substitution with ethanol.
- Lack of meaningful patent-based price protection.
Revenue can increase without a material rise in poisoning cases if list prices increase or supply becomes constrained. That type of growth would be less durable than volume-driven growth. Conversely, generic entry can lower price while preserving total unit demand.
The most plausible long-term profile is a defensible niche product with low absolute revenue, high clinical utility, and uneven annual sales. It is more attractive as part of a hospital-antidote portfolio than as a standalone growth asset.
What licensing deals affect fomepizole?
Fomepizole’s commercial history includes changes in ownership, marketing, and distribution associated with branded and specialty-pharmaceutical portfolios. Public company disclosures do not provide a consistent, standalone economic record for all licensing, distribution, or supply arrangements.
A transaction involving fomepizole should be evaluated on:
- Rights by country.
- Product and manufacturing ownership.
- Minimum purchase commitments.
- Hospital contract transferability.
- Shortage obligations.
- Regulatory responsibility.
- Inventory liability.
- Net pricing and gross-to-net deductions.
- Termination rights.
- Ability to add generic or alternative suppliers.
The value of a licensing deal is more likely to come from distribution reach and supply reliability than from patent exclusivity.
What geographic markets offer the strongest opportunity?
The United States is the most transparent market because FDA approval, poison-center infrastructure, hospital protocols, and Orange Book records provide identifiable regulatory and commercial markers.
Potentially attractive markets include regions with:
- Large emergency-care networks.
- High industrial solvent use.
- Established poison-control systems.
- Reliable hemodialysis access.
- Hospital antidote-stockpiling requirements.
- Limited access to pharmaceutical-grade ethanol.
International demand is fragmented. Regulatory approvals, hospital procurement, toxicology practice, and antidote availability differ by country. Geographic expansion can be operationally more important than patent expansion because the active ingredient itself is not strongly protected.
Key Takeaways
- Fomepizole is a mature, small-market emergency antidote for methanol and ethylene glycol poisoning.
- Antizol was FDA-approved in 1997; original exclusivity is no longer a commercial barrier.
- The molecule has weak current patent protection and limited formulation complexity.
- Paragraph IV litigation is not the main market risk.
- Generic entry pressure is high, but sterile manufacturing and low market volume limit sustained competition.
- Demand is episodic and driven by hospital stocking, poisoning incidence, treatment protocols, and product availability.
- Fomepizole has no biosimilar risk because it is a chemically synthesized small molecule.
- No manufacturer publicly discloses reliable standalone fomepizole revenue.
- Financial performance is likely to remain niche, with upside tied to pricing, supply reliability, and portfolio distribution rather than patient expansion.
- The strongest commercial moat is operational: regulatory compliance, sterile supply, emergency inventory, and hospital contracting.
FAQs
Is fomepizole a specialty pharmaceutical?
Yes. Fomepizole is a hospital-based emergency antidote rather than a conventional specialty drug with recurring outpatient prescriptions.
Can a generic company launch fomepizole without conducting a new clinical trial?
An ANDA applicant generally relies on the reference product’s safety and efficacy findings, subject to FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, manufacturing quality, and labeling.
Does fomepizole have orphan-drug pricing power?
Its use is rare, but rarity alone does not create current orphan exclusivity or prevent generic competition. Pricing power depends more on emergency clinical value and supply conditions.
Why can fomepizole remain expensive after patent expiry?
Hospitals value immediate availability, product shortages can reduce competition, sterile injectable manufacturing is costly, and the product may be stocked even when it is rarely used.
What is the main investment risk for a fomepizole supplier?
The main risks are low and unpredictable volume, generic price pressure, manufacturing interruption, inventory expiration, and hospital purchasing concentration.
References
-
U.S. Food and Drug Administration. (1997). Antizol (fomepizole) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
American Academy of Clinical Toxicology. (2002). Position paper on fomepizole therapy for toxic alcohol poisonings. Journal of Toxicology: Clinical Toxicology, 40(5), 683-685.
-
National Capital Poison Center. (2024). Methanol and ethylene glycol poisoning treatment guidance. Poison Control.
-
American Association of Poison Control Centers. (2023). Annual report of the National Poison Data System. AAPCC.
